United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $501.27 -2.04%
Financial Fact:
Income tax expense: -77.3M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Income tax expense: -77.3M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
